ArchiveJuly 2011

Exposing the Failure of EAE

You wrote “I would like someone to expose the greatest fraud in MS research – EAE and other mouse models that bear no resemblance to human MS……The complete failure to identify any effective treatments form this model is the biggest scandal/ fraud, unfortunately no one is prepared to rock the boat and own up to this”. Do not kid yourself there are always people who are prepared to rock the...

Cognitive deficits correlate with MRI changes in normal appearing brain tissue

Background:  The disease load in MS often is based on the visible lesion volume on MRI. The subtle changes in the  normal appearing brain tissue are rarely considered. Study objectives: This study investigated whether MRI changes in the normal appearing brain tissue explained part of the cognitive impairment seen in MS’ers   Results: In this study a significant...

Alemtuzumab – risks of developing other autoimmune diseases

Study objectives: To define the rate, timing, and clinical risk factors for the development of autoimmune disease after alemtuzumab treatment in MS’ers. “What is alemtuzumab? You may know the drug as Campath-1h. This is a powerful immuno-modulator that is given as a course of intravenous infusions. It depletes the immune system and allows it to recover. I refer to it as an...

Shoddy Media Reporting

You may have noticed stories about stem cell trials funded by the Multiple Sclerosis Society and the UK Stem Cell foundation MS Society Press Release Please ingnore much of the rubbish that has been appearing on some media websites. Queen Mary is not undertaking a trial of stem cells from aborted foetues, in fact the study is only a study in mice. This is another example of shoddy...

CCSVI: Zamboni should have declared his conflicts of interest

In response to a previous comment and my response. “I only realise now that most MS’ers are not aware of some very important background information in relation to CCSVI.” “The worrying and most upsetting thing about the whole CCSVI saga is the fact that Zamboni had, and still has, massive conflicts of interest. He has patents in relation to CCSVI and received money from a...

Professor David Baker: not just a pretty face

The fraud case he saw coming; well done Prof DB! Read all about it in Nature News & Science Insider. The paper David spotted: Van Parijs et al. Role of interleukin 12 and costimulators in T cell anergy in vivo. J Exp Med. 1997 Oct 6;186(7):1119-28. “Another one of our day jobs is to expose research fraud; unfortunately it is not always this...

Natalizumab PML incidence estimates by treatment period

There are now 145 confirmed PML cases as of July 5, 2011. Please note there has now been over 165,000 years of exposure to Natalizumab. Therefore the number of PML cases has to be seen in the context of the number of MS’ers receiving the drug.  The following graph provides the risk by treatment period.  *Yousry TA, et al. N Engl J Med. 2006;354:924-933. This is the observed rate...

Natalizumab risk stratification update

The following is an update of the natalizumab risk stratification figures based on: Prior use of immunosuppression; for example mitoxantrone. azathioprine, etc.  Treatment duration (months); please remember that the risk of PML within the first 12 months of therapy is very low. Anti-JCV antibody status (positive or negative); if you have not been tested for these antibodies you need to ask...

MS pathology is more extensive than previously thought

Background: The ‘normal appearing white matter’ in MS,  i.e. the areas without visible lesions, is known to be diffusely abnormal using special MRI techniques.  Results: Using a new stronger high-field MRI the investigators identified numerous lesions that were not detectable in areas of ‘normal appearing white matter’ as seen using conventional MRI. ...

CCSVI – NICE to review the procedure

NICE has been notified about CCSVI and will consider it as part of the Institute’s work programme. The Interventional Procedures Advisory Committee (IPAC) will consider this procedure and NICE will issue an Interventional Procedures Consultation Document about its safety and efficacy for 4 weeks public consultation.  IPAC will then review the consultation document in the light of comments...

Translate

Categories

Recent Posts

Recent Comments

Archives